• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Hematology

Sutimlimab improved hemoglobin and patient symptoms in cold agglutinin disease

byAvneesh BhanguandHarsh Shah
April 12, 2021
in Hematology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Sutimlimab was shown to stop hemolysis, improve hemoglobin levels, and reduce patient fatigue in patients with cold agglutinin disease.

2, Infections and gastrointestinal adverse events were determined to be related to sutimlimab treatment.

Evidence Rating Level: 2 (Good)

Study Rundown: Cold agglutinin disease is caused by autoantibodies binding to the I antigen on erythrocytes when temperatures are less than or equal to 37 °C, which activates the complement pathway causing agglutination. Currently, no approved therapies exist for cold agglutinin disease. Sutimlimab is a monoclonal antibody that targets C1s, which activates the complement pathway. This study assessed the efficacy and safety of sutimlimab in patients with cold agglutinin disease. Patients treated with sutimlimab had a rapid response in halting hemolysis, markedly increased hemoglobin levels, and improved fatigue levels. Mild-to-moderate adverse events, most commonly infections and gastrointestinal disorders, were also noted in patients treated with sutimlimab. Limitations of this study include a lack of a control treatment arm, a small sample size, and a lack of long-term follow-up data. Nonetheless, this study’s results are significant in showing that targeting the classic complement pathway represents a novel approach for treating cold agglutinin disease.

Click to read the study in NEJM

Relevant Reading: TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins

In-Depth [prospective cohort]: This study enrolled 24 patients at 16 sites across eight countries. Patients 18 years or older who had confirmed cold agglutinin disease, a recent red-cell infusion, hemoglobin levels 10g/dL or lower, and a total bilirubin level above normal range at screening were included in the study. Patients with cold agglutinin syndrome or a diagnosis of another autoimmune disorder with antinuclear antibodies were excluded from the study. The primary efficacy endpoint was a composite of normalization of hemoglobin levels to 12 g/dL or greater, or an increase by 2 g/dL from baseline. Overall, 13 of 24 patients (54%; 95% confidence interval [CI], 33 to 74) met the criteria for the composite primary endpoint. Activity in the classic complement pathway was almost completely inhibited within one week after the initiation of sutimlimab treatment. Patient-reported fatigue was reduced during sutimlimab treatment, as assessed by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (mean score at baseline, 32.5; mean score at time of treatment assessment, 44.3 [higher score indicated less fatigue]). Additionally, 124 adverse events occurred in 22 out of 24 patients (92%). The type and frequency of the most common adverse events were infections and infestations (54%), gastrointestinal disorders (33%), and administration-site conditions (29%). Altogether the results of this study show that in patients with cold agglutinin disease, sutimlimab treatment was associated with halted hemolysis, improved hemoglobin levels, and improved patient quality of life.

RELATED REPORTS

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

Betibeglogene autotemcel gene therapy effective for β-thalassemia

#VisualAbstract Adding a novel inflammatory marker to a scoring tool better predicted mortality in patients with epidermal necrolysis

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: classic complement pathwaycold agglutinin diseasehemoglobinsutimlimab
Previous Post

Mood disorders and outcomes of COVID-19 hospitalizations

Next Post

Direct oral anticoagulants more effective in patients with valvular atrial fibrillation

RelatedReports

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

April 14, 2022
Blood type correlates with egg reserve in infertile women
Chronic Disease

Betibeglogene autotemcel gene therapy effective for β-thalassemia

February 7, 2022
#VisualAbstract Adding a novel inflammatory marker to a scoring tool better predicted mortality in patients with epidermal necrolysis
StudyGraphics

#VisualAbstract Adding a novel inflammatory marker to a scoring tool better predicted mortality in patients with epidermal necrolysis

December 30, 2021
The REACH trial: hydroxyurea safe and effective for sickle cell anemia in African children
Chronic Disease

Hydroxyurea with dose escalation performs better than fixed-dose hydroxyurea in pediatric sickle cell disease

June 25, 2020
Next Post
Patient Basics: Thrombotic Stroke

Direct oral anticoagulants more effective in patients with valvular atrial fibrillation

Pediatric renal and thyroid cancer rates increase

Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.